Hamilton Lane Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Hamilton Lane Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-35,791	Closed	-$56.9K	–	66
2023 Q1	$56.9K	Hold	35,791	–	–	0.02%	59
2022 Q4	$52K	Hold	35,791	–	–	0.02%	67
2022 Q3	$153K	Sell	35,791 -35,700	-50%	-$151K	0.06%	59
2022 Q2	$277K	Hold	71,491	–	–	0.11%	57
2022 Q1	$340K	Hold	71,491	–	–	0.08%	61
2021 Q4	$261K	Hold	71,491	–	–	0.03%	81
2021 Q3	$573K	Buy	+71,491	New	+$705K	0.1%	62

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hamilton Lane Advisors's VIRX Position: Q2 2023 in Review

Hamilton Lane Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 35,791 shares — an estimated $56.9K sold.

Hamilton Lane Advisors first reported a position in VIRX in Q3 2021 and held it in 7 quarters. The position peaked at $573K in Q3 2021. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

Hamilton Lane Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Hamilton Lane Advisors sold 35,791 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $56.9K.
Hamilton Lane Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Hamilton Lane Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $573K in Q3 2021.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Hamilton Lane Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.